

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Comparative bioequivalence study of the Budesonide 9 mg, tablet manufactured by Tasnim Company

Protocol summary

Study aim

Examining the bioequivalency of the Budesonide 9-mg tablets manufactured by Tasnim Company with brand samples(Cortimen®)

Design

A single dose, not blinded, randomized, bioequivalence clinical trial on 24 healthy volunteers.

Settings and conduct

The number of 24 healthy in the age range of 18-60 years and the Body Mass Index range of 18-30, who are voluntarily selected through public notification. One tablet is taken fasting and blood is taken at 16 times point. One week later, the process is repeated for the brand medicine

Participants/Inclusion and exclusion criteria

The weight range of participating candidates should be between 60-100 kg; All candidates must be non-smokers; Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ -GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form.

Intervention groups

After taking a Budesonide 9-mg tablets from domestic company, 3 milliliters of blood will be collected from the volunteer in 16 times intervals for 72 hours. one week later, the process is repeated for a brand sample tablet. The drug concentration is measured in plasma

Main outcome variables

Studying the Drug pharmacokinetic parameters including measuring the plasma concentrations of drugs for brand and test products, determining the desired and important pharmacokinetic parameters in bioequivalence

studies, AUCs, Tmax, Cmax, T1/2

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20130313012810N23**

Registration date: **2024-01-21, 1402/11/01**

Registration timing: **retrospective**

Last update: **2024-01-21, 1402/11/01**

Update count: **0**

Registration date

2024-01-21, 1402/11/01

Registrant information

Name

Hamed Hamishehkar

Name of organization / entity

Drug Applied Research Center, Tabriz University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 41 1336 3311

Email address

hamishehkar.hamed@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-01-15, 1402/10/25

Expected recruitment end date

2024-01-19, 1402/10/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
Comparative bioequivalence study of the Budesonide 9 mg, tablet manufactured by Tasnim Company

Public title
Budesonide tablet bioequivalence

Purpose
Other

Inclusion/Exclusion criteria
Inclusion criteria:
The weight range of participating candidates should be between 60-100 kg Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (γ-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose Volunteers who have agreed to an informed consent form All candidates should not consume caffeine-containing drinks and chocolate during two days before the prescription, and this restriction must be followed until the last blood draw
Exclusion criteria:
History of allergic or adverse reaction to Budesonide or any similar product Volunteers with blood pressure less than 60/90 mm Hg or higher than 90/140 mm Hg Smokers Individuals who donated whole blood or blood components within 2 months within 2 weeks prior to the first dose of the study product(s)

Age
From **18 years** old to **60 years** old

Gender
Both

Phase
Bioequivalence

Groups that have been masked
No information

Sample size
Target sample size: **24**

Randomization (investigator's opinion)
Randomized

Randomization description
To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo

Not used

Assignment
Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Tabriz University of Medical Sciences

Street address

Daneshgah St. Drug Applied Research Center

City

Tabriz

Province

East Azarbaijan

Postal code

5165665811

Approval date

2023-12-18, 1402/09/27

Ethics committee reference number

IR.TBZMED.REC.1402.697

Health conditions studied

1

Description of health condition studied

Bioequivalence study in healthy volunteers

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Plasma concentration of the drug

Timepoint

16 sampling time included pre-dose (time 0) and at the following hours post-dose: 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 24, 48, and 72 h

Method of measurement

Liquid Chromatography with tandem mass spectrometry (LC-MS-MS)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: This study examines the bioequivalence of the Budesonide tablet produced by a domestic company with a foreign brand sample. We have only one intervention group and there is no control group. The intervention group, which includes healthy, fasting volunteers, will receive a single dose, 9 mg tablet manufactured by the pharmaceutical company Tasnim and Cortimen® brand, in two 72-hour periods with an interval of one week, on the day of the study. And in 16 different time periods up to 72 hours after taking the medicine, blood samples will be taken from the volunteers in the amount of 3 ml each time, that is, a total of 48 ml within 72 hours. The training that will be given to the volunteers includes avoiding the consumption of drinks containing alcohol and xanthine and other interfering drugs in the prescription drug from 48 hours before the start of the study until the end of the study.

Category

N/A

Recruitment centers**1****Recruitment center****Name of recruitment center**

Drug Applied Research Center, Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tasnim pharmaceutical Company

Full name of responsible person

Nazanin Nami Moghaddam

Street address

Tasnim Building, No. 3, 14th East Street, Beyhaghi Street, Argentina Square, Tehran

City

Tehran

Province

Tehran

Postal code

1515667911

Phone

+98 21 8817 4810

Email

info@tasnimpharma.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tasnim pharmaceutical Company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3181

Fax

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Web page address

<http://darc.tbzmed.ac.ir/>

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of

Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3181

Fax

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Web page address

<http://darc.tbzmed.ac.ir/>

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Hamed Hamishehkar

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Drug Applied Research Center, Tabriz University of

Medical Sciences

City

Tabriz

Province

East Azarbaijan

Postal code

51656-65811

Phone

+98 41 3336 3181

Fax

+98 41 3336 3311

Email

hamishehkar.hamed@gmail.com

Web page address

<http://darc.tbzmed.ac.ir/>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available